Company intelligence

STIM

Neuronetics, Inc. · NASDAQ · Healthcare

Price$2.90-2.68% · −$0.08

Market cap201.8MEquity value

P / E-6.6Trailing ratio

Volume96.81KLatest session

Market data

STIM price chart

TradingView

Related signals

1 min delayed

Browse public STIM signals with their source context and measured market impact. Open any signal for its permanent analysis page.

STIMJul 20, 2026-6.93% since signal

Neuronetics surge from Greenbrook TMS deal; BTIG sets $5 target

Neuronetics' Greenbrook TMS acquisition transforms it into a vertically integrated mental-health platform, adding TMS and Spravato. The Q1 beat and BTIG's Buy rating with a $5 target underscore near-term upside as the company expands. Strategic partnerships with Compass and ANT Neuro highlight growth in interventional therapies, though reimbursement and integration risks remain.

View signal analysis

STIMAug 13, 2024+14.23% since signal

Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook

Neuronetics to acquire Greenbrook in all-stock deal to enhance NeuroStar's reach. Merger expected to boost revenue growth and deliver $15 million in annual cost savings. Global mental health market projected to grow from $399.6 billion to $544.6 billion by 2031. Neuronetics launched BMP program, enhancing mental health treatment accessibility. STIM shares have declined 57.1% in the past year, underperforming the industry.

View signal analysis

Research